This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
2022 International Bladder Cancer Network
Viewing 21-40 of 42 articles
IBCN 2022: Quality of Life in Patients with High-Grade NMIBC Undergoing Standard Versus Reduced Frequency of BCG Instillations: Results of the EAU-RF NIMBUS-Trial
IBCN 2022: γδ T Cells Involvement in Bladder Cancer
IBCN 2022: Actionable Genomic Landscapes From a Real-World Cohort of Localized Urothelial Carcinoma Patients
IBCN 2022: Matrix Metalloproteineases in Blood and Urine Can Be Potential Biomarkers for Prediction of Bladder Cancer Outcome
IBCN 2022: Low Guideline Adherence to Recommended Use of Neoadjuvant Chemotherapy in Patients With Non-Metastatic Muscle-Invasive Bladder Cancer
IBCN 2022: Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-Based Neoadjuvant Chemotherapy in Bladder Cancer
IBCN 2022: Stromal Marker Fibroblast Activation Protein Drives Outcome in T1 Non-Muscle Invasive Bladder Cancer
IBCN 2022: Innovation and Novel Approach To the Treatment of NMIBC and MIBC
IBCN 2022: Abnormal Methylation of Selected Tumor Supressor Genes as Driving Factors Muscle Invasive, High Grade Bladder Cancer
IBCN 2022: Identification of Cisplatin Resistance Biomarkers for Urothelial Carcinoma by Mass Spectrometry and Tissue Microarray Analysis
IBCN 2022: Uromonitor®, BTA Stat®, Alere NMP22® BladderChek®, and UBC® Rapid Test in Comparison to Cytology as Tumor Marker for Urinary Bladder Cancer: New Results of a German Prospective Multicentre-Study
IBCN 2022: Surveillance of High-Grade Non-Muscle-Invasive Bladder Tumours Using the Xpert® Bladder Cancer Monitor: The DaBlaCa-15 Randomised Clinical Trial
IBCN 2022: Propensity Matched Comparison of Radical Cystectomy with Trimodality Therapy for Muscle Invasive Bladder Cancer: A Multi-Institutional Study
IBCN 2022: Updated Follow-up Data and Biomarker Analysis of Pre-operative Ipilimumab and Nivolumab in Locoregional Advanced Urothelial Cancer (NABUCCO)
IBCN 2022: Prospective Study on FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer
IBCN 2022: Associations Between Molecular Subtypes and Metastatic Sites in Urothelial Cancer
IBCN 2022: Single Nucleus RNA-Sequencing of Human Bladder Tumors Delineates Intra-Tumor Subtype Heterogeneity
IBCN 2022: Multi-Omic Profiling of Bladder and Ureteric Urothelium Reveals Regulatory Differences Pertinent to Urothelial Carcinoma Development Across the Urinary Tract
IBCN 2022: Predictive Value of Molecular Subtypes and APOBEC3G for Adjuvant Chemotherapy in Urothelial Bladder Cancer
IBCN 2022: Whole Genome Sequencing of 126 Early Age at Onset Bladder Cancer Patients Identifies Novel Candidate Risk Variants
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free